Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Analysts Are Cutting Their Estimates: Here's What You Need To Know
LENZ Therapeutics (NASDAQ:LENZ) recently released its yearly report, revealing revenues of US$19m, missing analyst predictions, and a statutory loss of US$2.85 per share, exceeding forecasts. Analysts have since cut next year’s revenue estimates to US$30.3m and increased loss per share forecasts to US$3.62, leading to a 13% drop in the consensus price target to US$44.43. Despite the downgraded outlook, the company is still expected to experience revenue growth significantly faster than the broader industry.